Fenofibrate
[CAS# 49562-28-9]

Identification

• Classification: API >> Circulatory system medication >> Regulating blood lipids
• Name: Fenofibrate
• Synonyms: 2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropanoic acid isopropyl ester; Proctofene; Sedufen
• Molecular Formula: C₂₀H₂₁ClO₄
• Molecular Weight: 360.84
• CAS Registry Number: 49562-28-9
• EC Number: 256-376-3
• SMILES: CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl

Properties

• Solubility: 100 mM (DMSO), 100 mM (ethanol) (Expl.)
• Density: 1.2±0.1 g/cm³, Calc.^*
• Melting Point: 81 ºC (Expl.)
• Index of Refraction: 1.547, Calc.^*
• Boiling Point: 469.8±35.0 ºC (760 mmHg), Calc.^*
• Flash Point: 165.4±24.9 ºC, Calc.^*

^* Calculated using Advanced Chemistry Development (ACD/Labs) Software.

Safety Data

• Hazard Symbols: GHS08 Warning
• Hazard Statements: H373-H413
• Precautionary Statements: P260-P273-P319-P501

Hazard Classification

Hazard	Class	Category Code	Hazard Statement
Specific target organ toxicity - repeated exposure	STOT RE	2	H373
Chronic hazardous to the aquatic environment	Aquatic Chronic	4	H413
Chronic hazardous to the aquatic environment	Aquatic Chronic	3	H412
Acute toxicity	Acute Tox.	4	H302
Reproductive toxicity	Repr.	2	H361
Acute toxicity	Acute Tox.	4	H332
Carcinogenicity	Carc.	2	H351

Discovory and Applicatios

Fenofibrate is a medication primarily used to reduce cholesterol levels in the blood. It belongs to a class of drugs known as fibrates, which are commonly prescribed to manage dyslipidemia, a condition characterized by abnormal levels of lipids, such as cholesterol and triglycerides, in the blood. Fenofibrate is used in the treatment of hypertriglyceridemia and mixed dyslipidemia, often as an adjunct to dietary changes and exercise.

Fenofibrate works by activating peroxisome proliferator-activated receptor alpha (PPAR-α), a nuclear receptor that plays a key role in the regulation of lipid metabolism. Activation of PPAR-α leads to an increase in the expression of genes involved in the breakdown of fatty acids and the reduction of triglyceride synthesis in the liver. As a result, fenofibrate helps lower triglyceride levels and increase high-density lipoprotein (HDL) cholesterol, often referred to as "good" cholesterol. In addition, fenofibrate may modestly reduce low-density lipoprotein (LDL) cholesterol, known as "bad" cholesterol.

The primary clinical benefit of fenofibrate is its ability to lower triglyceride levels, which is particularly important for patients at risk of cardiovascular disease, as elevated triglycerides are a significant risk factor. The medication is also used to increase HDL cholesterol, which has protective effects on the cardiovascular system by helping to remove excess cholesterol from the bloodstream and prevent the buildup of plaques in the arteries.

Fenofibrate is typically administered orally in the form of tablets or capsules. It is often prescribed when other measures, such as diet and exercise, have been insufficient to manage lipid levels. The medication is generally well-tolerated, but like all drugs, it can cause side effects in some patients. Common side effects include gastrointestinal issues such as nausea, diarrhea, and abdominal pain. More serious side effects, although rare, can include liver dysfunction, muscle pain (myopathy), and kidney problems, especially in patients with pre-existing kidney disease.

One important aspect of fenofibrate therapy is that it is often used in combination with other lipid-lowering agents, such as statins, for more effective management of dyslipidemia. However, the combination of fenofibrate and statins should be carefully monitored due to the potential increased risk of muscle-related side effects, particularly in older adults or those with kidney impairment.

In addition to its role in lipid management, fenofibrate has been studied for its potential to reduce the risk of atherosclerosis and cardiovascular events. Some studies have suggested that fenofibrate may help reduce inflammation and improve endothelial function, which could contribute to its cardiovascular protective effects. However, its role in primary prevention of cardiovascular disease remains less well-established compared to other therapies, such as statins.

In summary, fenofibrate is a widely used medication for managing hypertriglyceridemia and mixed dyslipidemia. It works by activating PPAR-α to reduce triglyceride levels and increase HDL cholesterol, thus improving lipid profiles and reducing the risk of cardiovascular disease. While it is generally well-tolerated, it can cause side effects, and its use should be closely monitored, especially in combination with other lipid-lowering drugs like statins.

References

1998. Long-Term Efficacy and Safety of Fenofibrate and a Statin in the Treatment of Combined Hyperlipidemia. The American Journal of Cardiology, 81(4).
DOI: 10.1016/s0002-9149(98)00040-x

1998. Clinical Pharmacokinetics of Fibric Acid Derivatives (Fibrates). Clinical Pharmacokinetics, 34(2).
DOI: 10.2165/00003088-199834020-00003

1984. Fenofibrate therapy of hypertriglyceridaemias. Differential effects on LDL cholesterol level in Type IV and in Type IIb primary hyperlipoproteinaemia. European Journal of Clinical Pharmacology, 27(5).
DOI: 10.1007/bf00541935